- Home
- BLRX vs QNRX Comparison
BLRX vs QNRX Comparison
Compare BLRX & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | QNRX |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 14.5M |
| IPO Year | 2010 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BLRX | QNRX |
|---|---|---|
| Price | $2.30 | $5.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 13.0K | ★ 119.5K |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $5.47 |
| 52 Week High | $7.77 | $41.80 |
Technical Indicators
Market Signals| Indicator | BLRX | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 37.66 |
| Support Level | $2.15 | $5.47 |
| Resistance Level | $2.51 | $6.98 |
| Average True Range (ATR) | 0.10 | 0.51 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 31.99 | 19.86 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.